'Sor­ry, Es­cape Bio closed': A neu­rode­gen­er­a­tive up­start ex­its bid to ri­val Bio­gen-De­nali

A neu­rode­gen­er­a­tive dis­ease-fo­cused biotech that was at­tempt­ing to go up against the bil­lion-dol­lar pair­ing of Bio­gen and De­nali has shut­tered, End­points News has learned.

Es­cape Bio had built a pipeline of three small mol­e­cules for pa­tients with forms of Nie­mann-Pick Type C, Parkin­son’s and Alzheimer’s and wooed a who’s who of biotech in­vestors. Bankrollers in­clud­ed the VC arms of J&J and No­var­tis, Welling­ton Cap­i­tal Man­age­ment, Or­biMed, No­vo Hold­ings, Sut­ter Hill Ven­tures, Sur­vey­or Cap­i­tal and more than half a dozen oth­ers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER